17Such an interpretation is, in GEAES’s view, consistent with the Court’s case-law resulting, inter alia, from the judgments of 16 October 1997, Fillibeck (C‑258/95, EU:C:1997:491), and of 11 December 2008, Danfoss and AstraZeneca (C‑371/07, EU:C:2008:711).
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.